Fetal and Neonatal Alloimmune Thrombocytopenia Clinical Trial
Official title:
A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
The purpose of this Phase 2 study is to assess the pharmacokinetics (PK) and safety of RLYB212 in HPA-1b/b pregnant women at higher risk for HPA-1a alloimmunization and FNAIT.
This study is a single-arm, open-label, multicenter study of RLYB212 in HPA-1b/b pregnant participants at higher risk for the occurrence of HPA-1a alloimmunization and FNAIT. A laboratory testing paradigm will be applied at screening to identify women at higher risk for HPA-1a alloimmunization. Study IPA2202 is comprised of three phases: a two-part screening phase, an antenatal treatment phase, and a postpartum follow-up phase. Study duration for each participant is anticipated to be ~44 weeks, inclusive of the screening visits through the Week 10 postpartum visit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05345561 -
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
|
||
| Completed |
NCT04067375 -
Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
|
||
| Enrolling by invitation |
NCT04529382 -
Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia
|
||
| Completed |
NCT03561909 -
Kinetics of Blood Platelets Transfused to Healthy Subjects
|
N/A |